The multinational panel overseeing the trial endorsed that finding and will “communicate with the principal investigators in the trial about resuming the hydroxychloroquine arm of the trial,” Tedros said.
Hydroxychloroquine is one of four medicines under review as potential coronavirus treatments in the Solidarity trial, which Tedros said has enrolled more than 3,500 participants in 35 countries.
WHO officials stressed that they were not endorsing hydroxychloroquine’s overall safety or efficacy as a COVID-19 remedy.
“We hope that the ongoing trials will continue until we have definitive answers,” said Soumya Swaminathan, the WHO’s chief scientist.
Source: politico.com
See more here: news365.stream
loading...
